Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Pain. 2022 Nov 14;164(6):1340–1354. doi: 10.1097/j.pain.0000000000002824

Figure 11. Schematic of multiple benefits of 3-oxa-PD1 and mechanism of action.

Figure 11.

Local and systemic injection of 3-oxa-PD1 reduces acute, persistent, and chronic itch in mouse models. 3-oxa-PD1 inhibits central sensitization in spinal cord neurons by modulation of both excitatory and inhibitory synaptic transmission in CTCL mice. Furthermore, 3-oxa-PD1 can suppress spinal cord production and astrocyte release of LCN2, an astrocyte-produced itch mediator.